Brexpiprazole (Rexulti): the gentler partial agonist

Brexpiprazole, sold as Rexulti, was approved by the FDA in 2015 as a "next-generation" partial dopamine agonist — designed to retain aripiprazole's metabolic friendliness while reducing the akathisia and activation that drive many patients off aripiprazole. It is structurally similar but pharmacologically tuned differently. In 2023 it became the first FDA-approved medication for agitation associated with Alzheimer's disease.

What brexpiprazole is

Brexpiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors — the same broad mechanism as aripiprazole, but with a slightly different binding profile that translates to different clinical effects. The full FDA prescribing information is available through Drugs@FDA.

What it treats

• Schizophrenia in adults
• Adjunctive treatment of major depressive disorder — added to an antidepressant
• Agitation associated with dementia due to Alzheimer's disease — first FDA-approved medication for this indication, 2023

The dementia agitation indication is meaningful but comes with the same boxed warning that applies to all antipsychotics in elderly patients with dementia: increased mortality risk. The decision to use it in this population requires careful balancing.

Typical dosing range

FDA-labelled adult dose ranges differ by indication. For schizophrenia, the typical range is 2 to 4 mg once daily. For depression as an adjunct, lower doses (around 1 to 3 mg). For Alzheimer's-related agitation, doses are individualised. Specific dosing should always come from your prescriber.

How it differs from aripiprazole

Brexpiprazole has lower intrinsic activity at the D2 receptor than aripiprazole — meaning it acts as a "gentler" partial agonist. Clinically, this often translates to:

• Less akathisia
• Less activation/insomnia
• Slightly more sedation in some patients
• Slightly more weight gain (still modest compared to many atypicals)

For patients who responded well to aripiprazole but couldn't tolerate the restlessness, brexpiprazole is often considered.

Common side effects

• Weight gain — modest; more than aripiprazole, less than olanzapine
• Akathisia — present but generally less than aripiprazole
• Sedation
• Increased appetite
• Headache
• Tremor

Serious side effects

Brexpiprazole shares aripiprazole's risk of impulse-control disorders, with the same FDA warnings about pathological gambling and similar behaviours. It also carries the standard antipsychotic boxed warnings.

What patients commonly say

• "I tried aripiprazole and the restlessness was unbearable; brexpiprazole was much smoother."
• "It helped my depression when added to my antidepressant."
• "I gained a little weight — about 8 pounds in six months."
• "It's expensive without good insurance."

Questions for your prescriber

• Why brexpiprazole specifically rather than aripiprazole or another option?
• What's the target dose for my situation?
• What metabolic monitoring will we do?
• Are there any compulsive behaviours you'd want me to report?
• Is brexpiprazole covered by my insurance?

Putting it together

Brexpiprazole is a useful refinement of the partial agonist concept — particularly for patients who did well on aripiprazole but couldn't tolerate the activation. It is also an important option in adjunctive depression treatment. Cost can be a real barrier, as the brand-name product is more expensive than older generics. As with all antipsychotics, the choice is best made with a prescriber who knows your full clinical picture.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.